Document:

<PAGE>

                                                                    EXHIBIT 10.4

                          CONFIDENTIAL TREATMENT REQUESTED BY VITAL LIVING, INC.

                                                                   REDACTED COPY

                                 AMENDMENT NO. 1
                                       to
                        DEVELOPMENT AND LICENSE AGREEMENT

This Amendment No. 1 to Development and License Agreement (this "Amendment"), is
entered into as of August 20, 2003 by and among:

(1)      e-nutriceuticals, Inc., a Delaware corporation ("e-nut");

(2)      Vital Living, Inc., a Nevada corporation ("Vital Living");

(2)      Jagotec AG, a Swiss Corporation; and

(3)      SkyePharma PLC, a company incorporated in England and Wales.

                              W I T N E S S E T H:

                  WHEREAS, e-nut and SkyePharma PLC have entered into a
Development and License Agreement, dated as of December 28, 2001 (the "DLA");

                  WHEREAS, on January 23, 2002 all rights and obligations of
SkyePharma PLC under the DLA were assigned to its wholly owned subsidiary
Jagotec AG (which for the purposes of this Amendment shall be referred to as
"Skye");

                  WHEREAS, e-nut and Skye desire to amend the DLA in certain
respects, subject to the terms, conditions and limitations hereof;

                  WHEREAS, e-nut, Vital Living and VLEN Acquisition Corporation
expect to enter into an Agreement and Plan of Merger (the "Merger Agreement")
immediately after the execution of this Amendment; and

                  WHEREAS, the parties hereto desire to provide for the
assignment of the DLA, as amended hereby, by e-nut to Vital Living concurrently
with the consummation of the transactions contemplated by the Merger Agreement.

                  NOW, THEREFORE, in consideration of the mutual promises and
conditions set forth below, the parties agree as follows:

ARTICLE ONE - AMENDMENTS

1.0      Interpretation. Capitalized terms used herein but not otherwise defined
herein shall have the meanings ascribed thereto in the DLA.

1.1      Amendment of Exhibit 1. Exhibit 1 attached to this Amendment is the
Skye Patent Exhibit 1 referred to in Section 1. (o) i) of the DLA.

<PAGE>

                          CONFIDENTIAL TREATMENT REQUESTED BY VITAL LIVING, INC.

1.2      Amendment of Section 2.1. Section 2.1 is hereby amended and restated to
read in its entirety as follows:

"2.1     Products. Through the period up to ***, (i) e-nut shall have the
exclusive right to identify up to *** product candidates in the Field for
Development using the Skye Technology (each, a "Product"), (ii) Skye shall not
have the right to license the Technology (or any Joint Patent) to third parties
for products in the Field and (iii) Skye shall not have the right to use the
Technology (or any Joint Patent) to independently develop products in the Field.

The Parties acknowledge and agree that as of the date of this Amendment, *** of
the *** Products have been identified and formulated and *** product remains to
be identified and formulated, and all *** products have been paid for. The ***
product is to be identified prior to ***. In the event of the *** Product not
being identified by ***, e-nut's rights to identify a *** Product under Section
2.1(i) will terminate and be of no further effect."

1.3      Amendment of Section 2.2. Section 2.2 is amended and restated in its
entirety as follows:

"Section 2.2. Additional Products.

         (a) Beginning on ***, e-nut shall have the right until *** to identify
additional product candidates in the Field (each, an "Additional Product") for
Development using the Skye Technology, provided, however, that: (i) at least ***
Additional Products are identified by e-nut in each calendar year and all ***
Additional Products are capable of being formulated by Skye (as determined by
Skye in its reasonable judgment), or (ii) beginning on *** Skye receives Product
Development Fees of at least *** from e-nut (or any affiliate) in each calendar
year as adjusted for inflation in accordance with Section 3.2.

         (b) The terms and conditions upon which Skye would formulate the
Additional Products are to be negotiated in good faith by e-nut and Skye but in
any event shall be no worse than the terms for the development of the first six
Products specified in Section 3.2 of the DLA.

         (c) The rights of e-nut to submit annual Additional Products shall
extend beyond *** if the Skye Patents extend beyond such date, and in such
case, ***.

         (d) For the avoidance of doubt, in the event that *** new Additional
Products are not acceptable to Skye in accordance with Section 2.2(a) during the
calendar year of *** or any calendar year thereafter, then, exclusivity shall
terminate at the end of such calendar year and Skye shall have the right to
license the Technology (or any joint Patent) to third parties for products in
the Field and the right to independently develop products in the field. As to
any new Additional Products submitted by e-nut after such termination of
exclusivity, such products may be licensed at SkyePharma's option on a
non-exclusive basis, it being acknowledged that all prior Additional Products
shall remain subject to the exclusive marketing rights of e-nut.

<PAGE>

                          CONFIDENTIAL TREATMENT REQUESTED BY VITAL LIVING, INC.

         (e) Notwithstanding the foregoing, in the event that Skye determines
that an Additional Product is not capable of being formulated by Skye (in
accordance with Section 2.2(a)), it shall not count as an Additional Product for
purposes of determining whether four Additional Products have been submitted.

         (f) e-nut will pay to Skye ***.

1.4      Amendment of Section 2.4. The second sentence of Section 2.4, which
reads:

"The License will be exclusive until ***, after which date the License will be
non-exclusive save with respect to Products and Additional Products and Skye may
grant licenses within the Field to other parties."

shall be deleted in its entirety and replaced with the following:

"The License will be exclusive until ***, subject to extension(s) thereof for
the life or extension(s) thereof of the Skye Patents. The License shall however
become non-exclusive on *** of any year, beginning on *** if in the preceding
calendar year the conditions of Section 2.2 (a) are not fulfilled."

1.5      Amendment of Section 2.5 (ii). Section 2.5 (ii) of the agreement which
reads:

"agrees to pay Skye quarterly in arrears royalties equal to *** of e-nut's Net
Sales of Products or Additional Products during the term of this Agreement where
the Product or Additional Product and its exploitation under the terms of this
Agreement are covered by a Valid Claim."

shall be deleted in its entirety and replaced with the following:

"agrees to pay Skye quarterly in arrears royalties equal to *** of e-nut's Net
Sales of Products or Additional Products until the last to expire of the Valid
Claims covering the Product or Additional Product and thereafter until e-nut
ceases to derive revenues from or make sales of such Products or Additional
Products."

1.6      Amendment of Section 2. Section 2 is hereby amended by the addition of
a new Section 2.6 and Section 2.7, which shall read in their entirety as
follows:

"2.6     Marketing in China. e-nut is hereby appointed as Skye's exclusive
marketing partner to pharmaceutical companies for the licensing of all Skye
Technology (including the Geomatrix technology) relating to the delivery of
drugs or other vitamins or nutraceuticals, whether existing now or herein after
created, in the Peoples Republic of China, Taiwan and Hong Kong (the "Chinese
Territory"). For each Introduction made or facilitated by e-nut which results in
any fees or revenues being paid to Skye or any of Skye's Affiliates in the
Chinese Territory, Skye shall pay to e-nut a royalty equal to *** of such gross
fees or revenues, payable on the same terms and conditions as the other royalty
payments set forth in this Agreement. Gross fees and revenues shall include all
cash

<PAGE>

                          CONFIDENTIAL TREATMENT REQUESTED BY VITAL LIVING, INC.

compensation excluding those for research and development for purposes of
computing the royalty payment.

On each *** of ***, if Skye shall not have received as of such *** *** (as
adjusted for inflation as of such date in accordance with the inflation
adjustment methodology established in Section 3.2) in gross cash fees and
revenues in the *** prior to such *** date generated by Introductions made or
facilitated by e-nut (which gross cash fees and revenues for purposes of this
calculation shall not include any research and development fees but shall for
the *** periods ended on the *** of *** include any payments for research and
development pursuant to feasibility studies ("Adjusted Revenues")), then unless
Skye shall have received as of the next following *** date an aggregate of ***
(as adjusted for inflation as of such date in accordance with the inflation
adjustment methodology established in Section 3.2) in Adjusted Revenues in
respect of the *** period ending on such *** date generated by Introductions
made or facilitated by e-nut, (i) exclusivity shall terminate as of such date
and (ii) Skye shall thereafter not be bound by any of the provisions of this
Section 2.6 and shall retain all rights with respect to the Chinese Territory,
which shall include the right to directly or indirectly market its products in
the Chinese Territory for the purpose of licensing the Skye Technology without
any obligation to make any payment to e-nut; provided, however, that Skye will
be required to continue to pay the *** payment referred to above, which shall
remain payable, and shall be paid, during the duration of the relevant Skye
Patent to the extent that revenues are derived from an Introduction.

For purposes of this Agreement, the term "Introduction" shall mean ***.

"2.7     Additional License Fees. In consideration of additional rights granted
by this Amendment in respect of (i) Section 2.1 and 2.2, of the DLA, e-nut
hereby pays to Skye a one time fee of *** by the issuance to Skye of *** shares
of Common Stock of e-nut, convertible into *** shares of Common Stock of Vital
Living on the terms and conditions set out in the Merger Agreement, Subscription
Agreement and Registration Rights Agreement of even date herewith ("TRANSACTION
AGREEMENTS"), and (ii) Section 2.6, e-nut hereby pays to Skye a one time fee of
*** by issuance to Skye of *** shares of Common Stock of e-nut convertible into
*** shares of Common Stock of Vital Living, on the terms and conditions set out
in the Transaction Agreements."

1.7      Amendment of Section 10. Section 10.1 is amended and restated in its
entirety as follows:

"10.1    Term. Unless terminated by the parties pursuant to Sections 10.2 and
10.3 below, this Agreement shall remain in effect until e-nut ***.
Notwithstanding the foregoing, the rights granted to e-nut under Sections 2.1,
2.2, and 2.3 above shall terminate with respect to a particular Product or
Additional Product upon the Abandonment of such Product or Additional Product;
provided however, that e-nut may continue to refer to such abandoned Product in
its promotional or other materials (subject to Section 6)."

1.8      Amendment to Section 11.1. Section 11.1 is amended and restated in its
entirety as follows:

<PAGE>

                          CONFIDENTIAL TREATMENT REQUESTED BY VITAL LIVING, INC.

11.1     Assignment. This Agreement and the licenses herein granted shall be
binding upon and shall inure to the benefits of the parties, their Affiliates
and successors; provided that e-nut and its permitted assignee may not assign
its rights, duties or obligations under this Agreement without the prior written
consent of Skye except for the assignment and assumption effected pursuant to
the Assignment and Assumption Agreement dated as of August 20, 2003.

ARTICLE TWO - REPRESENTATIONS

2.1      Representations of Skye. Skye represents and warrants that as of the
date hereof (i) the DLA is in full force and effect and (ii) there are no facts
known to Skye which would reasonably serve as a basis of any claim that Skye
does not have the right to use or license the Skye Technology to e-nut as
contemplated by the DLA as amended hereby. Skye has not licensed or otherwise
transferred, or entered into any agreement, commitment or arrangement (whether
oral or written) to license or otherwise transfer, to any other person any of
the Skye Technology or any rights thereto or interests therein, which now, or
with the passage of time will, conflict with or impair the rights to and
interest in the Skye Technology transferred to e-nut pursuant to the DLA as
amended hereby.

2.2      Representations of e-nut with Respect to the Amendment Shares. E-nut
represents and warrants to Skye that all corporate action on the part of e-nut,
its officers, directors and stockholders necessary for the authorization,
execution and delivery of this Amendment, including the issuance of the shares
of Common Stock of e-nut (the "Amendment Shares") referred to in Section 1.6 of
this Amendment (containing new Section 2.7 of the DLA) has been taken. Upon
issuance in accordance with the DLA as amended, the Amendment Shares will be
validly issued, fully-paid and nonassessable, and free from all preemptive
rights.

ARTICLE THREE - ASSIGNMENT

3.1      Assignment. Each of Vital Living and e-nut agree to execute the
Assignment and Assumption Agreement, attached hereto as Exhibit 2, immediately
upon the execution of this Amendment.

3.2      Acknowledgement. Skye and Vital Living acknowledge and agree that upon
the execution of such Assignment and Assumption Agreement, Vital Living will
succeed e-nut as a party to the DLA, as amended hereby, with all the rights,
remedies, duties and obligations held by e-nut under the DLA, as amended hereby.

ARTICLE FOUR - GENERAL PROVISIONS

4.1      Full Force and Effect. Upon (i) the execution of this Amendment by each
of the parties hereto and (ii) the consummation of the merger contemplated by
the Merger Agreement, the terms of the DLA shall be as amended hereby. Except as
expressly amended hereby, the DLA and all other documents, agreements and
instruments relating thereto, are and shall remain, unmodified and in full force
and effect.

<PAGE>

                          CONFIDENTIAL TREATMENT REQUESTED BY VITAL LIVING, INC.

4.2      Choice of Law. The validity, performance, construction, and effect of
this Amendment shall be governed by the laws of the State of New York.

4.3      Dispute Resolution. In the case of any disputes between the parties
arising from this Amendment, Section 11.7 of the DLA shall apply.

4.4.     Counterparts. This Amendment may be executed in counterparts, each of
which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

4.6      Compliance with Laws. If any provision of this Amendment is found by
any court or administrative body of competent jurisdiction to be invalid or
unenforceable, such invalidity or unenforceability shall not affect the other
provisions of this Amendment which shall remain in full force and effect. If any
provision of this Amendment is so found to be invalid or unenforceable but would
be valid or enforceable if some part of the provision were deleted or amended,
the provision in question shall apply with such modification(s) as may be
necessary to make it valid and enforceable.

                            [Signature Page Follows]

<PAGE>

                          CONFIDENTIAL TREATMENT REQUESTED BY VITAL LIVING, INC.

         IN WITNESS WHEREOF, the parties have executed this Agreement.

                                    E-NUTRICEUTICALS, INC.

                                    By__________________________________
                                    Stephen Morris
                                    Sole Officer and Director

                                    VITAL LIVING, INC.

                                    By__________________________________
                                    Stuart Benson
                                    President

                                    By__________________________________
                                    Brad Edson
                                    Chief Executive Officer

                                    JAGOTEC AG

                                    By__________________________________
                                    Name:
                                    Title:

                                    SKYEPHARMA PLC

                                    By__________________________________
                                    Name:
                                    Title:<PAGE>

                                                                     EXHIBIT 4.4

[NOTE: THIS FORM OF NOTE IS TO BE AUTHENTICATED AND DELIVERED UPON THE EXCHANGE
OF 4.625% NOTES DUE 2010 DULY TENDERED PURSUANT TO THE EXCHANGE OFFER TO BE
CONSUMMATED PURSUANT TO A REGISTRATION RIGHTS AGREEMENT, DATED AS OF JULY 18,
2003, AMONG THE COMPANY AND THE INITIAL PURCHASERS REFERRED TO THEREIN.]

REGISTERED                                                            REGISTERED

NO.                                                             PRINCIPAL AMOUNT

CUSIP NO. 25159 AF0                                                 $300,000,000

                                 [FACE OF NOTE]

                    DEVELOPERS DIVERSIFIED REALTY CORPORATION

                              4.625% Notes Due 2010

                  UNLESS THIS NOTE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE
OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION ("DTC"), TO DEVELOPERS
DIVERSIFIED REALTY CORPORATION (THE "COMPANY") OR ITS AGENT FOR REGISTRATION OF
TRANSFER, EXCHANGE OR PAYMENT AND ANY NOTE ISSUED IS REGISTERED IN THE NAME OF
CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE
OF DTC AND ANY PAYMENT IS MADE TO CEDE & CO., OR TO SUCH OTHER ENTITY AS IS
REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC, ANY TRANSFER, PLEDGE, OR OTHER
USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS
THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

                  UNLESS AND UNTIL THIS NOTE IS EXCHANGED IN WHOLE OR IN PART
FOR NOTES IN CERTIFICATED FORM, THIS NOTE MAY NOT BE TRANSFERRED EXCEPT AS A
WHOLE BY DTC TO A NOMINEE THEREOF OR BY A NOMINEE THEREOF OR BY A NOMINEE
THEREOF TO DTC OR ANOTHER NOMINEE OF DTC OR BY DTC OR ANY SUCH NOMINEE TO A
SUCCESSOR OF DTC OR A NOMINEE OF SUCH SUCCESSOR.

                  DEVELOPERS DIVERSIFIED REALTY CORPORATION, an Ohio corporation
(herein referred to as the "Company", which term includes any successor
corporation under the Indenture referred to on the reverse hereof), for value
received, hereby promises to pay to CEDE & CO., c/o The Depository Trust
Company, 55 Water Street, New York, New York 10041, or registered assigns, the
principal sum of THREE HUNDRED MILLION Dollars ($300,000,000)
<PAGE>
on August 1, 2010 (the "Stated Maturity Date"), unless redeemed prior to such
date in accordance with the provisions referred to on the reverse hereof (the
Stated Maturity Date or date of earlier redemption, as the case may be, is
referred to herein as the "Maturity Date" with respect to the principal payable
on such date), and to pay interest thereon from July 18, 2003 or from the most
recent Interest Payment Date to which interest has been paid or duly provided
for, on February 1 and August 1 of each year commencing February 1, 2004 (each,
an "Interest Payment Date"), and on the Maturity Date, at a rate of 4.625% per
annum, until the principal hereof is paid or duly provided for.

                  The interest so payable, and punctually paid or duly provided
for, on any Interest Payment Date and on the Maturity Date will, as provided in
such Indenture, be paid to the Holder in whose name this Note (or one or more
predecessor Notes) is registered at the close of business on the Regular Record
Date for such interest, which shall be fifteen calendar days (whether or not a
Business Day, as defined below) next preceding such Interest Payment Date or the
Maturity Date, as the case may be (each, a "Regular Record Date"). Any such
interest not so punctually paid or duly provided for shall forthwith cease to be
payable to the Holder on such Regular Record Date, and may be paid to the Holder
in whose name this Note (or one or more Predecessor Notes) is registered at the
close of business on a Special Record Date for the payment of such Defaulted
Interest to be fixed by the Trustee referred to on the reverse hereof, notice
whereof shall be given to Holders of Notes of this series not less than 10 days
prior to such Special Record Date, or may be paid at any time in any other
lawful manner not inconsistent with the requirements of any securities exchange
on which the Notes of this series may be listed, and upon such notice as may be
required by such exchange, all as more fully provided in the Indenture.

                  The principal of this Note payable on the Maturity Date will
be paid against presentation and surrender of this Note at either of the offices
or agencies of the Company maintained for that purpose in the Borough of
Manhattan, The City of New York and Cleveland, Ohio. The Company hereby appoints
National City Bank as Paying Agent for the Notes where Notes of the series may
be presented and surrendered for payment and where notices, designations or
requests in respect of payments with respect to the Notes may be served.

                  Interest payable on this Note on any Interest Payment Date and
on the Maturity Date, as the case may be, will include interest accrued from and
including the next preceding Interest Payment Date in respect of which interest
has been paid or duly provided for (or from and including July 18, 2003, if no
interest has been paid on this Note) to but excluding such Interest Payment Date
or the Maturity Date, as the case may be. If any Interest Payment Date or the
Maturity Date falls on a day that is not a Business Day, as defined below,
principal, premium, if any, and/or interest payable with respect to such
Interest Payment Date or Maturity Date, as the case may be, will be paid on the
next succeeding Business Day with the same force and effect as if it were paid
on the date such payment was due, and no interest shall accrue on the amount so
payable for the period from and after such Interest Payment Date or Maturity
Date, as the case may be. "Business Day" means any day, other than a Saturday or
Sunday, on which banks in the Borough of Manhattan, the City of New York, are
not required or authorized by law or executive order to close.

                  All payments of principal, premium, if any, and interest by
the Company in respect of this Note will be made by wire transfer of immediately
available funds.

                                       2

<PAGE>

                  Reference is hereby made to the further provisions of this
Note set forth on the reverse hereof, which further provisions shall for all
purposes have the same effect as if set forth at this place.

                  Unless the Certificate of Authentication hereon has been
executed by the Trustee by manual signature of one of its authorized
signatories, this Note shall not be entitled to any benefit under the Indenture,
or be valid or obligatory for any purpose.

                                       3

<PAGE>

                  IN WITNESS WHEREOF, the Company has caused this instrument to
be duly executed under its corporate seal.

Dated:

                                           DEVELOPERS DIVERSIFIED
                                             REALTY CORPORATION

                                           By:______________________________
                                              Name:
                                              Title:

Attest:

_______________________________
Name:
Title:

                     TRUSTEE'S CERTIFICATE OF AUTHENTICATION

                  This is one of the Securities of the series designated therein
referred to in the within-mentioned Indenture.

Dated:

                                           NATIONAL CITY BANK, as
                                             Trustee

                                           By:______________________________
                                              Authorized Officer

                                       4

<PAGE>

                                [REVERSE OF NOTE]

                    DEVELOPERS DIVERSIFIED REALTY CORPORATION

                              4.625% Notes Due 2010

                  This Note is one of a duly authorized issue of securities of
the Company (herein called the "Securities"), issued and to be issued in one or
more series under an Indenture, dated as of May 1, 1994, as supplemented by the
First Supplemental Indenture dated as of May 10, 1995 and the Second
Supplemental Indenture dated as of July 18, 2003 (herein called the
"Indenture"), between the Company and National City Bank, as Trustee (herein
called the "Trustee", which term includes any successor trustee under the
Indenture with respect to the series of which this Note is a part), to which the
Indenture and all indentures supplemental thereto reference is hereby made for a
statement of the respective rights, limitations of rights, duties and immunities
thereunder of the Company, the Trustee and the Holders of the Securities, and of
the terms upon which the Securities are, and are to be, authenticated and
delivered. This Note is one of the duly authorized series of Securities
designated as "4.625% Notes Due 2010" (collectively, the "Notes"), and the
aggregate principal amount of the Notes to be issued under such series is
limited to $300,000,000 (except for Notes authenticated and delivered upon
transfer of, or in exchange for, or in lieu of other Notes). All terms used but
not defined in this Note shall have the meanings assigned to such terms in the
Indenture.

                  If an Event of Default shall occur and be continuing, the
principal of the Securities of this series may be declared due and payable in
the manner and with the effect provided in the Indenture.

                  This Notes may be redeemed at the option of the Company, at
any time in whole or from time to time in part, at a Redemption Price equal to
the greater of (1) 100% of the principal amount of the Notes being redeemed, or
(2) the sum of the present values of the remaining scheduled payments of
principal and interest on the Notes being redeemed (not including the portion of
any payments of interest accrued to the Redemption Date) discounted to the
Redemption Date on a semi-annual basis (assuming a 360-day year consisting of
twelve 30-day months) at the Treasury Rate plus 25 basis points, plus, in each
case, any interest accrued but not paid to the date of redemption. For the
avoidance of doubt, any calculation of the remaining scheduled payments of
principal and interest pursuant to clause (2) of the preceding sentence shall
not include interest accrued as of the applicable Redemption Date.

                  "Treasury Rate" means, with respect to any Redemption Date for
the Notes, (i) the yield under the heading which represents the average for the
immediately preceding week, appearing in the most recently published statistical
release designated "H.15(519)" or any successor publication which is published
weekly by the Board of Governors of the Federal Reserve System and which
established yields on actively traded United States Treasury securities adjusted
to constant maturity under the caption "Treasury Constant Maturities," for the
maturity corresponding to the Comparable Treasury Issue (if no maturity is
within three months before or after the Maturity Date, yields for the two
published maturities most closely corresponding to the Comparable Treasury Issue
shall be determined and the Treasury Rate shall be interpolated or extrapolated
from such yields on a straight line basis, rounding to the nearest month) or
(ii) if

<PAGE>

such release (or any successor release) is not published during the week
preceding the calculation date or does not contain such yields, the rate per
annum equal to the semi-annual equivalent yield to maturity of the Comparable
Treasury Issue, calculated using a price for the Comparable Treasury Issue
(expressed as a percentage of its principal amount) equal to the Comparable
Treasury Price for such Redemption Date. The Treasury Rate shall be calculated
by the Independent Investment Banker on the third Business Day preceding the
Redemption Date.

                  "Comparable Treasury Issue" means the United States Treasury
security selected by the Independent Investment Banker as having a maturity
comparable to the remaining term of the Notes to be redeemed that would be
utilized, at the time of selection and in accordance with customary financial
practice, in pricing new issues of corporate debt securities of comparable
maturity to the remaining term of such Notes.

                  "Independent Investment Banker" means one of the Reference
Treasury Dealers that has been appointed by the Company.

                  "Comparable Treasury Price" means with respect to any
Redemption Date for the Notes (i) the average of four Reference Treasury Dealer
Quotations for such Redemption Date, after excluding the highest and lowest such
Reference Treasury Dealer Quotations, or (ii) if the Trustee obtains fewer than
four such Reference Treasury Dealer Quotations, the average of all such
quotations.

                  "Reference Treasury Dealer" means each of Banc of America
Securities LLC and J.P. Morgan Securities Inc. and the respective successors and
any two of Banc One Capital Markets, Inc., Commerzbank Capital Markets Corp.,
Deutsche Bank Securities Inc., Goldman, Sachs & Co., Lehman Brothers Inc.,
Morgan Stanley & Co. Incorporated, Wachovia Capital Markets, LLC and Wells Fargo
Brokerage Services, LLC and their respective successors (each, a "Primary
Treasury Dealer") provided, however, that if any of the foregoing shall cease to
be a Primary Treasury Dealer, the Company shall substitute in its place another
Primary Treasury Dealer.

                  "Reference Treasury Dealer Quotations" means, with respect to
each Reference Treasury Dealer and any Redemption Date, the average, as
determined by the Trustee, of the bid and asked prices for the Comparable
Treasury Issue (expressed in each case as a percentage of its principal amount)
quoted in writing to the Trustee by such Reference Treasury Dealer at 5:00 p.m.
on the third Business Day preceding such Redemption Date.

                  Notice of any redemption will be mailed by the first-class
mail at least 30 days but not more than 60 days before the Redemption Date to
each Holder of Notes to be redeemed. If the Company redeems less than all of the
Notes, the Trustee will select the particular Notes to be redeemed pro rata, by
lot or by another method the Trustee deems fair and appropriate.

                  This Note is not subject to any sinking fund.

                  The Indenture contains provisions for defeasance of (i) the
entire indebtedness of the Notes or (ii) certain covenants and Events of Default
with respect to the Notes, in each case upon compliance with certain conditions
set forth therein, which provisions apply to the Notes.

<PAGE>

                  The Indenture permits, with certain exceptions as therein
provided, the amendment thereof and the modification of the rights and
obligations of the Company and the rights of the Holders of the Securities under
the Indenture at any time by the Company and the Trustee with the consent of the
Holders of not less than a majority of the aggregate principal amount of all
Securities issued under the Indenture at the time Outstanding and affected
thereby. The Indenture also contains provisions permitting the Holders of not
less than a majority of the aggregate principal amount of the Outstanding
Securities, on behalf of the Holders of all such Securities, to waive compliance
by the Company with certain provisions of the Indenture. Furthermore, provisions
in the Indenture permit the Holders of not less than a majority of the aggregate
principal amount of the Outstanding Securities of any series, in certain
instances, to waive, on behalf of all of the Holders of Securities of such
series, certain past defaults under the Indenture and their consequences. Any
such consent or waiver by the Holder of this Note shall be conclusive and
binding upon such Holder and upon all future Holders of this Note and other
Notes issued upon the registration of transfer hereof or in exchange herefor or
in lieu hereof, whether or not notation of such consent or waiver is made upon
this Note.

                  No reference herein to the Indenture and no provision of this
Note or of the Indenture shall alter or impair the obligation of the Company,
which is absolute and unconditional, to pay the principal of, premium, if any,
and interest on this Note at the times, places and rate, and in the coin or
currency, herein prescribed.

                  As provided in the Indenture and subject to certain
limitations therein and herein set forth, the transfer of this Note is
registrable in the Security Register of the Company upon surrender of this Note
for registration of transfer at the office or agency of the Company in any place
where the principal of, premium, if any, and interest on this Note are payable,
duly endorsed by, or accompanied by a written instrument of transfer in form
satisfactory to the Company and the Security Registrar duly executed by, the
Holder hereof or by his attorney duly authorized in writing, and thereupon one
or more new Notes, of authorized denominations and for the same aggregate
principal amount, will be issued to the designated transferee or transferees.

                  As provided in the Indenture and subject to certain
limitations therein and herein set forth, this Note is exchangeable for a like
aggregate principal amount of Notes of different authorized denominations but
otherwise having the same terms and conditions, as requested by the Holder
hereof surrendering the same.

                  The Notes are issuable only in registered form without coupons
in denominations of $1,000 and any integral multiple thereof.

                  No service charge shall be made for any such registration of
transfer or exchange, but the Company may require payment of a sum sufficient to
cover any tax or other governmental charge payable in connection therewith.

                  Prior to due presentment of this Note for registration of
transfer, the Company, the Trustee and any agent of the Company or the Trustee
may treat the Person in whose name this Note is registered as the owner hereof
for all purposes, whether or not this Note be overdue,

<PAGE>

and neither the Company, the Trustee nor any such agent shall be affected by
notice to the contrary.

                  The Indenture and the Notes shall be governed by and construed
in accordance with the laws of the State of Ohio applicable to agreements made
and to be performed entirely in such State.

<PAGE>

                                  ABBREVIATIONS

                  The following abbreviations, when used in the inscription on
the face of this instrument, shall be construed as though they were written out
in full according to applicable laws or regulations.

                  TEN COM    -     as tenants in common

                  TEN ENT    -     as tenants by the entireties

                  JT TEN     -     as joint tenants with right of survivorship
                                   and not as tenants in common

                  UNIF GIFT MIN ACT _____________ Custodian _____________
                                       (cust)                  (Minor)

                        under Uniform Gifts to Minors Act

                         ______________________________
                                     (State)

                    Additional abbreviations may also be used
                          though not in the above list

                         ______________________________

<PAGE>

                                   ASSIGNMENT

                  FOR VALUE RECEIVED, the undersigned hereby sell(s), assign(s)
and transfer(s) unto____________________________________________________________

________________________________________________________________________________

PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE

         _________________________________________________
         _________________________________________________

________________________________________________________________________________

________________________________________________________________________________

                   (Please print or typewrite Name and Address
                     including Postal Zip Code of Assignee)

________________________________________________________________________________

the within Note and all rights thereunder, and hereby irrevocably constitutes
and appoints____________________________________________________________________

________________________________________________________________________________

to transfer said Note on the books of the Company, with full power of
substitution in the premises.

Dated: Signature Guaranteed

______________________________________  ________________________________________
NOTICE: Signature must be guaranteed    NOTICE: The signature to this assignment
by a member firm of the New York Stock  must correspond with the name as written
Exchange or a commercial bank or trust  upon the face of the within Note in
company.                                every particular, without alteration or
                                        enlargement or any change whatever.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00056-of-00352.parquet"}]]